Paradoxical tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) was first described almost two decades ago. We undertook this systematic review and meta-analysis to collate findings across studies that have reported the incidence, clinical features, management and outcomes of paradoxical TB-IRIS. Forty studies that cumulatively reported 1048 paradoxical TB-IRIS cases were included. The pooled estimated incidence among patients with HIV-associated TB initiating antiretroviral therapy was 18% (95% CI: 16-21%). Frequent features were pulmonary and lymph node involvement. Hospitalization occurred in 25% (95% CI: 19-30%). In studies that reported treatment, corticosteroids were prescribed more frequently (38%; 95% CI: 27-48%) than nonsteroidal anti-inflammatory drugs (28%; 95% CI: 2-53%). Case fatality was 7% (95% CI: 4-11%), but death attributed to TB-IRIS occurred in 2% of cases (95% CI: 1-3%).
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.2217/fmb.15.9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Paradoxical Tuberculosis Immune Reconstitution Inflammatory Syndrome Complicated by Large Bilateral Psoas Abscess: A Case Report.
J Int Assoc Provid AIDS Care
October 2024
Universidad Nacional Mayor de San Marcos, Instituto de Medicina Tropical Daniel A. Carrion, Lima, Peru.
Immune reconstitution inflammatory syndrome is a common manifestation in human immunodeficiency virus (HIV)-positive patients infected with tuberculosis (TB). One of the unusual complications of this condition is the development of psoas abscess. We describe a case of immune reconstitution inflammatory syndrome (IRIS) in a patient with disseminated TB under treatment, HIV-positive with a low CD4 cell count, complicated by bilateral psoas abscess.
View Article and Find Full Text PDFNo increased risk of tuberculosis-related immune reconstitution inflammatory syndrome with integrase inhibitor-based antiretroviral therapy in people with HIV with profound immunosuppression.
HIV Med
November 2024
Department of Health, Tuberculosis and Chest Service, Public Health Services Branch, Centre for Health Protection, Hong Kong, China.
Introduction: The issue of whether integrase inhibitors (INSTIs) may confer a higher risk of paradoxical tuberculosis-related immune reconstitution inflammatory syndrome (TB-IRIS) compared with other classes of antiretroviral in people with HIV with a profound level of immunosuppression remains insufficiently explored. We aimed to assess whether such a higher risk exists by examining a cohort of patients with TB-HIV initiating antiretroviral therapy (ART) in Hong Kong.
Methods: This was a retrospective review of 133 patients registered in the TB-HIV Registry of the Department of Health during the period 2014-2021.
Incidence and pattern of tuberculosis immune reconstitution inflammatory syndrome (TB-IRIS) in patients on anti-retroviral therapy: An observational study.
Indian J Tuberc
July 2024
Department of Pharmacology, S.C.B. Medical College and Hospital, Cuttack, Odisha, India. Electronic address:
Article Synopsis
- Tuberculosis-immune reconstitution inflammatory syndrome (TB-IRIS) is a severe immune reaction against tuberculosis seen in individuals with HIV, often triggered by antiretroviral therapy (ART) that boosts immunity.
- An observational study at S.C.B. Medical College evaluated 286 HIV/AIDS patients on ART, revealing a 7.7% incidence of TB-IRIS, with a notable difference in the occurrence of paradoxical vs. ART-associated TB-IRIS.
- The study found significant increases in CD cell counts and differences in plasma viral loads before and after TB-IRIS onset, highlighting the need for careful monitoring of HIV patients for TB coinfection.
Tuberculosis and Immune Reconstitution Inflammatory Syndrome in Patients With Inflammatory Bowel Disease and Anti-TNFα Treatment: Insights From a French Multicenter Study and Systematic Literature Review With Emphasis on Paradoxical Anti-TNFα Resumption.
Open Forum Infect Dis
July 2024
Service de Médecine Interne, Hôpital Beaujon, Assistance Publique des Hôpitaux de Paris, Clichy, France.
Article Synopsis
- Anti-TNFα therapy has transformed the treatment of inflammatory bowel disease (IBD), but it poses a risk for developing active tuberculosis (TB) and potential complications like immune reconstitution inflammatory syndrome (IRIS).
- A French retrospective study analyzed 36 IBD patients with TB treated with anti-TNFα, finding a high incidence of disseminated TB and a significant rate of IRIS, particularly in those with miliary TB.
- Most patients resumed anti-TNFα treatment safely after managing TB, with a favorable overall recovery rate, indicating that restarting this therapy can be an effective approach.
Tuberculosis (TB) is a global health threat, especially in HIV patients who may experience immune reconstitution inflammatory syndrome (IRIS) upon infection. Diagnosing and defining IRIS in non-HIV patients remains challenging. A 63-year-old male with acute leukaemia underwent induction therapy with a regimen containing fludarabine.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!